^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug: | sirolimus (mTOR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
Excerpt:
Adjuvant therapies…Adjuvant therapy is not recommended for HCC patients after OLT, LR or local ablation. Mammalian target of rapamycin (mTOR) inhibitors are used as immunosuppressant to prevent graft rejection in liver transplantation (sirolimus) but have failed to improve recurrence-free survival…
DOI:
10.1093/annonc/mdy308
